gilead’s next chapter

Confidential – Internal Use Only

Gilead’s Next ChapterDaniel O’DayChairman and Chief Executive OfficerJanuary 13, 2020


Forward-Looking StatementsStatements included in this presentation that are not historical in nature could be deemed forward-looking statements within the meaning of the PrivateSecurities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could causeactual results to differ materially from those referred to in the forward-looking statements. These risks and uncertainties include: Gilead’s ability to successfullyexecute its corporate strategy in its currently anticipated timelines; Gilead’s ability to accelerate or sustain revenues for its HIV and other programs; Gilead’sability to initiate clinical trials in its currently anticipated timelines; Gilead’s ability to realize the potential benefits of collaborations or licensing arrangements,including with Galapagos and other partners; Gilead’s ability to submit new drug applications for new product candidates in the timelines currently anticipated,including additional indications for filgotinib and Kite’s cell therapy candidates; Gilead’s ability to receive regulatory approvals in a timely manner or at all, fornew and current products, including regulatory approval of filgotinib for the treatment of RA and KTE-X19 for the treatment of mantle cell lymphoma; Gilead’sability to successfully commercialize its products, including expansion in China; safety and efficacy data from clinical studies may not warrant furtherdevelopment of Gilead’s product candidates, including filgotinib, GS-6207 capsid inhibitor and Kite’s cell therapy candidates; the risk that private and publicpayers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products; market share and price erosion caused by theintroduction of generic versions of our products; the risk that physicians and patients may not see advantages of Gilead’s products over other therapies andmay therefore be reluctant to prescribe the products; and other risks identified from time to time in Gilead’s reports filed with the U.S. Securities and ExchangeCommission (the SEC). There may be other factors of which Gilead is not currently aware that may affect matters discussed in the forward-looking statementsand may also cause actual results to differ significantly from these estimates. Gilead directs readers to its press releases, Quarterly Report on Form 10-Q forthe quarter ended September 30, 2019 and other subsequent disclosure documents filed with the SEC. Gilead claims the protection of the Safe Harborcontained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. All forward-looking statements are based on informationcurrently available to Gilead and Gilead assumes no obligation to update or supplement any such forward-looking statements other than as required by law.Any forward-looking statements speak only as of the date hereof or as of the dates indicated in the statements.

2


Three Pillars of Gilead’s Next Chapter

3

Strategy to Drive Additional Growth

Durable Core Business

Existing Pipeline Opportunities

+ +


Key Decisions Have Laid the Foundation for Change

4

2020Mar Jul Sep Oct Dec

Made KiteSeparate Operating

Company

Expanded Galapagos Partnership

Established External Innovation

Group

Completed New Leadership

Team

Defined New Corporate Strategy

2019


Diverse, Highly Experienced Leadership Team

5

Merdad Parsey, MD, PhD

Chief Medical Officer

Brett A. PletcherExecutive Vice President,

Corporate Affairs and General Counsel

Christi ShawChief Executive Officer, Kite

Taiyin Yang, PhDExecutive Vice President,

Pharmaceutical Development and Manufacturing

Daniel O’DayExecutive Chairman and Chief Executive Officer

Andrew DickinsonChief Financial Officer

Jyoti MehraExecutive Vice President,

Human Resources

Johanna MercierChief Commercial Officer

William A. Lee, PhDExecutive Vice President,

Research


Building from Durable Core Business

6




+ +


Robust Growth of HIV Business Despite Competitor Launches

7

2011 2019

• Antiviral world-leader

‒ 15 launches in 10 years1

• Robust HIV growth‒ 14% CAGR since 20112

‒ 13% growth Q3’18 – Q3’19

Prepared for Truvada U.S. LOE

HCVOtherHIV

• Treatment - 90-95% Gilead patients expected on F/TAF-based regimens by Q4’203

• Prevention - 40-45% individuals on PrEP expected to be on Descovy by Q4’203

1 Complera, Viread, Truvada for PrEP, Stribild, Tybost, Vitekta, Sovaldi, Harvoni, Genvoya, Odefsey, Epclusa, Vemlidy, Vosevi, Biktarvy, Descovy for PrEP. 2 Q1 2011 through Q3 2019. 3 Expectations for U.S. patients.


Expect Biktarvy® to remain preferred treatment option for majority of patients through 2033

HIV Franchise is Robust and Sustainable

8

• Zero cases of treatment-emergent resistanceand rapid start recommended1,2

• #1 prescribed HIV regimen and best HIV launch in history3,4

• ~80% average QoQ growth since launch

Highly effective single tablet regimen for treatment

Statistically significant safety improvements in prevention5

• ~20% at-risk individuals on PrEP today6

• ~25% PrEP scripts are for Descovy®

1 Biktarvy demonstrated zero cases of treatment-emergent resistance through 3 years in P3 clinical trials. 2 2018 DHHS treatment guidelines. 3 Biktarvy #1 prescribed HIV regimen in U.S. in Q3 2019. 4 Biktarvy best HIV launch in history in U.S. and certain other countries basedon prescription volume. 5 Statistically significant advantages with respect to all six pre-specified secondary endpoints for renal and bone laboratory parameters in patients receiving Descovy compared to Truvada. 6 ~1.1m at-risk individuals in U.S., 224k on PrEP, Q3 2019.


Capsid has the potential to be first- and best-in-class with multiple dosing options

Reinforcing Commitment to HIV Leadership With Innovative Long-Acting Programs

9

1 GS-6207 received breakthrough therapy designation from FDA as a potential therapy for heavily treatment-experienced (HTE) people living with multi-drug resistant HIV. 2 Pivotal for HTE patients. Selected pre-clinical assets displayed. INSTI - Integrase Strand Transfer Inhibitor. NRTI - Nucleoside reverse transcriptase inhibitor. NNRTI - Non-nucleoside reverse transcriptase inhibitor. bNAbs - Broadly neutralizing antibodies.

• Weekly oral potential

• Monthly 6 month SQ with self-admin potential

• Breakthrough Designation1

HTE2 P2/3

Virologically Suppressed P2

PrEP PC

Current Clinical Programs

Treatment+

Prevention

Capsid Inhibitor as the Foundation

Committed to Developing Multiple Partner Agents

LA INSTI • LA NRTI • LA NNRTI • bNAbs


Additional Opportunities to Grow Antiviral Business

10

1 Combined market share of Gilead branded or authorized generic partner products in U.S. 2 8 products approved in China since Sept 2017 including Sovaldi, Epclusa, Genvoya, Vemlidy, Harvoni, Descovy, Biktarvy and Vosevi and 4 products added to National ReimbursementDrug List (NRLD) including Vemlidy, Epclusa, Genvoya, Harvoni for Jan 2020 reimbursement.

Sustain HCV Revenues

Key market leadership~60% U.S. market share today1

Accelerate HBV

Achieve $1bn+ franchise by 2022 through U.S. and China Vemlidy

growth

Drive China Growth

8 products approved since 20174 listed on NRDL for Jan 2020

reimbursement2


Executing on Existing Pipeline Opportunities

11




+ +


Clinical Stage Programs

NDA/BLA/MAA, P3 and Registrational P2 trials

NMEs via in-licensing, options, and product acquisitions

Breakthrough Therapy Designations

Overview of Clinical Pipeline Today

12

41

14

13

4

Phase 1 Phase 2 Phase 3 NDA/BLA/MAA

Viral Diseases

Fibrotic Diseases

Inflammatory Diseases

Oncology


Filgotinib Marks Expansion into Inflammation with Potential for 5 Launches in Next 4 Years

13

RA P3

UC P3

CD P3

PsA P3

AS P2

Uveitis P2

Selective JAK-1 inhibitor with potential best-in-class profile

Strong efficacy for remission and demonstrated safety at both doses; favorable benefit/risk profile at high dose

Submitted for RA in U.S., Europe and Japan

P3 UC data in H1 2020

Filgotinib

Prepared for competitive RA launch with highly experienced team

RA - Rheumatoid Arthritis. UC - Ulcerative Colitis. CD - Crohn’s Disease. PsA - Psoriatic Arthritis. AS - Ankylosing Spondylitis.


Building a Broad Inflammation and Fibrosis Portfolio with Galapagos Beyond Filgotinib

141 Excluding filgotinib. 2 Autotaxin inhibitor. 3 GPR84 antagonist. 4 Toledo – dual mechanism anti-inflammatory. IPF - Idiopathic Pulmonary Fibrosis. OA – Osteoarthritis. Selected pre-clinical and P1 assets displayed.

Selected programs

8 clinical programs1

>20 pre-clinical programs

Doubles Gilead’s R&D footprint and accelerates transformational

therapy development

GLPG-43994 – Inflammation PCGLPG-4124 – Fibrosis PCGLPG-4259 – Inflammation PCGLPG-4471 – Inflammation PC

GLPG-16902 – IPF P3GLPG-1972 – OA P2GLPG-12053 – IPF P2

GLPG-39704 – Inflammation P1GLPG-33124 – Inflammation P1

GLPG-16902 – Systemic Sclerosis P2GLPG-0555 – Inflammation P1

GS-4997 (ASK1 inhibitor) – DKD P2

SM inh. (Neutrophil target) – Inflam. PCSM inh. (Innate immunity target) – Inflam. PC

GS-4875 (TPL2 inhibitor) – UC P2GS-5718 (IRAK4) – Inflammation PCGS-1427 (α4β7) – Inflammation PC

Cilo/Firco/Sel (FXR, ACC, ASK1) Combination – NASH P2

Key: Fibrotic Diseases; Inflammatory Diseases

GLPG-3667 – Inflammation P1


Building transformative therapies across complementary Immuno-Oncology platforms

Oncology Strategy Focused onImmuno-Oncology

1 Nearly half of r/r DLBCL patient alive three years after treatment with Yescarta in ZUMA-1 study. IO – Immuno-Oncology.

Pioneering platform to advance new therapies and

drive long-term growth

Apply small molecule and biologics development capabilities to IO

Transformative therapy with potential for earlier lines and additional indications1

Cell Therapy Non-Cell Therapy

15


Cell Therapy Non-Cell Therapy

Oncology Pipeline Consists of 15 Clinical Programs and Growing

Building transformative therapies across complementary Immuno-Oncology platforms

KTE-X19 CD-19 r/r MCL BLA

Axi-cel CD-19 2L DLBCL P3

Axi-cel CD-19 iNHL P21

Axi-cel CD-19 1L DLBCL P2

Axi-cel CD-19 DLBCL (+ritux. or lenal.) P21

KTE-X19 Adult ALL P21

KTE-X19 Pediatric ALL P21

KTE-X19 CLL P1

Axi-cel DLBCL (+4-1BB mAb) P1

MAGE A3/A6 TCR Solid tumors P1

HPV-16 E7 TCR Solid tumors P1

Allogeneic CD-19 r/r DLBCL PC

CLL-1 CAR T AML PC

Dual antigen CAR T r/r DLBCL PC

Oral PD-L1 inhibitor (GS-4224) Solid tumors P1

Anti-CD73/TGFβ TRAP (GS-1423)2 Solid tumors P1

Bi-specific mAb (AGEN1223)3,4 Multiple P1

Anti-CD137 mAb (AGEN2373)4 Multiple P1

Flt3R agonist (GS-3583) Solid tumors PC

MCL1 inhibitor (GS-9716) Multiple PC

Small molecule inh. (T cell target) Solid tumors PC

Small molecule inh. (TME target) Solid tumors PC

Monoclonal antibody (TME target) Solid tumors PC

16

1 Pivotal P2 study. 2 TME conditioning anti-CD73/TGFβ TRAP bifunctional fusion protein (GS-1423). 3 Bi-specific mAb targeting immunosuppressive regulatory T cells (AGEN1223). 4 Exclusive option to license rights from Agenus upon proof of concept data. ALL - Acute lymphocytic leukemia. CLL - Chronic lymphocytic leukemia. DLBCL - Diffuse large B-cell lymphoma. iNHL - Indolent non-Hodgkin lymphoma. MCL - Mantle cell lymphoma. r/r - relapsed refractory. iNHL - Indolent non-Hodgkin lymphoma. Selected pre-clinical assets displayed.

Confidential – Internal Use Only17HTE – heavily treatment-experienced.

Anticipated Milestones Through 2021

2021H2 2020H1 2020

FilgotinibP3 UC data

FilgotinibExpected RA approvals in U.S., Europe, Japan

FilgotinibP3 enrollment completion for CD

GLPG-1972P2 OA data

Capsid inhibitorP1 initiation for PrEP

GLPG-1690P3 IPF futility analysis data

Capsid inhibitorExpected HTE submission

Axi-celExpected iNHL approval

KTE-X19Expected aALL approval

Axi-celP2 1L DLBCL data

Axi-celExpected 2L DLBCL submission

KTE-X19Expected MCL approval

Axi-celP3 2L DLBCL data

Axi-celP2 iNHL data

FilgotinibMANTA/MANTA-RAy enrollment completion



18




+ +


New Corporate Strategy to Drive Future Growth

19

Long

-Ter

m

Ambi

tions

Stra

tegi

c

Prio

ritie

s

Bring 10+ Transformative Therapies to Patients by 2030

Be the Biotech Employer and Partner of Choice

Deliver Shareholder Value in a Sustainable, Responsible Manner

Strengthen Portfolio Strategy and Decision-

Making

Increase Patient Accessand Benefit

Continue to Evolveour Culture

Expand Internal andExternal Innovation


Focused on Growing from Core Areas of Strength

20

AntiviralsDeep Expertise

Immuno-modulationEmerging Expertise

Core Strengths Disease Areas

ViralDiseases

InflammatoryDiseases

Oncology FibroticDiseases


We Will Continue to Pursue Tailored Transactions That Drive Strategic Value

21

Guiding Principles for Future Deals

• Focus on high quality science that build upon core areas of strength

• Prioritize clinical and commercial opportunities

• Pursue and execute:

‒ Partnerships from small to transformative in size

‒ Bolt-on acquisitions from small to medium in size

32Strategic Partnerships

& Investment TransactionsOver the Past Two Years


Three Pillars of Gilead’s Next Chapter

22

Well positioned to maximize near-term opportunities and achieve long-term success




+ +


Gilead’s Next ChapterDaniel O’DayChairman and Chief Executive OfficerJanuary 13, 2020


Appendix


Viral Disease Pipeline

251 Biktarvy HIV treatment pediatric label extension. 2 Registrational for heavily treatment-experienced (HTE) patients. Selected pre-clinical assets displayed.

Pre-Clinical Phase 1 Phase 2 Phase 3

HIV

Biktarvy HIV treatment pediatric1

Capsid inhibitor (GS-6207) HIV HTE Registrational for HTE2

Capsid inhibitor (GS-6207) HIV virologically suppressedVesatolimod (GS-9620, TLR-7 agonist) HIV cureElipovimab (GS-9722, bNAb) HIV cureCapsid inhibitor (GS-6207) PrEPUnboosted protease inhibitor (GS-1156) HIV treatmentLong-acting oral combination therapy HIV treatmentHookipa vaccine HIV cure

HBV

Selgantolimod (GS-9688,TLR-8 agonist) HBV cureSpringBank compound (GS-9992) HBV curePD-L1 inhibitor (GS-4224) HBV cureHookipa vaccine (GS-6679) HBV cure

Confidential – Internal Use Only26^ Optionable partner program. Selected pre-clinical assets displayed.

Inflammatory Disease PipelinePre-Clinical Phase 1 Phase 2 Phase 3 NDA/BLA/MAA

Infla

mm

ator

y D

isea

se

Filgotinib (GS-6034, JAK-1 inhibitor) Rheumatoid arthritis NDA/MAA

Filgotinib (GS-6034, JAK-1 inhibitor) Ulcerative colitisFilgotinib (GS-6034, JAK-1 inhibitor) Crohn’s diseaseFilgotinib (GS-6034, JAK-1 inhibitor) Psoriatic arthritisFilgotinib (GS-6034, JAK-1 inhibitor) Ankylosing spondylitisFilgotinib (GS-6034, JAK-1 inhibitor) UveitisTPL2 inhibitor (GS-4875) Ulcerative colitisGLPG-1972^ OsteoarthritisGLPG-0555^ Inflammatory diseasesGLPG-3312^ Inflammatory diseasesGLPG-3970^ Inflammatory diseasesGLPG-3667 Inflammatory diseasesIRAK4 inhibitor (GS-5718) Inflammatory diseasesα4β7 inhibitor (GS-1427) Inflammatory diseasesSmall molecule inh. (Neutrophil target) Inflammatory diseasesSmall molecule inh. (Innate immunity target) Inflammatory diseasesGLPG-4399^ Inflammatory diseasesGLPG-4259^ Inflammatory diseasesGLPG-4471^ Inflammatory diseasesGLPG-4059^ Inflammatory diseases


Fibrotic Disease Pipeline

27* Optioned partner program. ^ Optionable partner program. Selected pre-clinical assets displayed.

Pre-Clinical Phase 1 Phase 2 Phase 3

Fibr

otic

Dis

ease

Cilofexor (GS-9674, FXR agonist) PSCGLPG-1690* Idiopathic pulmonary fibrosisCilofexor (FXR agonist), Firsocostat (ACC inh.), Selonsertib (ASK1 inh.) combinations NASH

Selonsertib (GS-4997, ASK1 inhibitor) DKDGLPG-1690* Systemic sclerosis GLPG-1205^ Idiopathic pulmonary fibrosisGLPG-4124^ Fibrosis


Oncology Pipeline

28

1 TME conditioning anti-CD73/TGFβ TRAP bifunctional fusion protein (GS-1423). 2 Bi-specific mAb targeting immunosuppressive regulatory T cells (AGEN1223). 3 Exclusive option to license rights from Agenus upon proof of concept data. ALL - Acute lymphocytic leukemia.CLL - Chronic lymphocytic leukemia. DLBCL - Diffuse large B-cell lymphoma. iNHL - Indolent non-Hodgkin lymphoma. MCL - Mantle cell lymphoma. r/r - relapsed refractory. iNHL - Indolent non-Hodgkin lymphoma. Selected pre-clinical assets displayed.

Pre-Clinical Phase 1 Phase 2 Phase 3 NDA/BLA/MAA

Cel

l The

rapy

KTE-X19 MCL BLA

Axi-cel 2L DLBCLAxi-cel Indolent NHL Pivotal

Axi-cel 1L DLBCLAxi-cel DLBCL (+rituximab or lenalidomide) Pivotal

KTE-X19 Adult ALL Pivotal

KTE-X19 Pediatric ALL Pivotal

KTE-X19 CLLAxi-cel DLBCL (+4-1BB mAb)KITE-718 (MAGE A3/A6) Solid tumorKITE-439 (HPV E7) Solid tumorAllogeneic CD-19 r/r DLBCLCLL-1 CAR T AMLDual antigen CAR T r/r/ DLBCL

Non

-Cel

l The

rapy

Oral PD-L1 inhibitor (GS-4224) Solid tumoranti-CD73/TGFβ TRAP (GS-1423)1 Solid tumorBi-specific mAb (AGEN1223)2,3 MultipleAnti-CD137 mAb (AGEN2373)3 MultipleFlt3R agonist (GS-3583) Solid tumorsMCL1 inhibitor (GS-9716) MultipleSmall molecule inhibitor (T cell target) Solid TumorsSmall molecule inhibitor (TME target) Solid TumorsMonoclonal antibody (TME target) Solid Tumors

gilead’s next chapter

Documents